Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Otalgia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    6 result(s) found for: Otalgia. Displaying page 1 of 1.
    EudraCT Number: 2014-004016-11 Sponsor Protocol Number: 2305 Start Date*: 2016-06-30
    Sponsor Name:University of Bristol
    Full Title: What is the clinical and cost effectiveness of benzocaine/phenazone ear drops for reducing antibiotic consumption and ear pain in children aged between 6 months and 10 years presenting to primary c...
    Medical condition: Acute otitis media
    Disease: Version SOC Term Classification Code Term Level
    20.0 10013993 - Ear and labyrinth disorders 10014020 Ear pain PT
    20.1 10013993 - Ear and labyrinth disorders 10065838 Middle ear inflammation PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-003463-22 Sponsor Protocol Number: CLOTOT3-16IA03 Start Date*: 2020-04-29
    Sponsor Name:Laboratorios Salvat, S.A.
    Full Title: A Phase III, Multicenter, Randomized, Double-Blind Clinical Trial to Assess the Efficacy and Safety of Clotrimazole 1% Otic Solution Compared to Placebo for the Treatment of Fungal Otitis Externa (...
    Medical condition: Fungal Otitis Externa (Otomycosis)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10052557 Otitis externa fungal PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) PT (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2004-000738-34 Sponsor Protocol Number: HMR3647B/3001 Start Date*: 2005-09-20
    Sponsor Name:Aventis Pharmaceuticals, Inc.
    Full Title: Multinational, randomized, double-blind, double-dummy, comparative study to evaluate the efficacy and safety of telithromycin 25 mg/kg given once daily for 5 or 10 days depending on age and previou...
    Medical condition: Acute otitis media in children.
    Disease: Version SOC Term Classification Code Term Level
    7 10021881 2
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004637-47 Sponsor Protocol Number: EFC6132,HMR3647B/3002 Start Date*: 2015-03-17
    Sponsor Name:Sanofi-aventis
    Full Title: Multinational, Randomized, Double-Blind, Double-Dummy, Comparative Study to Evaluate the Efficacy and Safety of 5 Days Telithromycin 25mg/kg od Versus 5 Days Azithromycin 10 mg/kg od Followed by 5 ...
    Medical condition: Otitis Media, Suppurative Otitis Media, Purulent
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10033092 Otitis media suppurative LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-004077-32 Sponsor Protocol Number: BCRU/11/Ibu-AOM/001 Start Date*: 2015-12-29
    Sponsor Name:Berlin-Chemie AG
    Full Title: A randomized open-label, multinational, multicentre, phase III clinical study to evaluate the efficacy and safety of Ibuprofen oral suspension 20 mg/ml and Ibuprofen oral suspension 40 mg/ml (Berli...
    Medical condition: Acute otitis media (AOM) is an acute inflammatory disease involving the mucosa of the middle ear. AOM is one of the most frequent complications of upper respiratory tract infections in children. T...
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-005319-30 Sponsor Protocol Number: 217917 Start Date*: 2022-11-02
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase 3b, open-label, multi-country, multi-centre, long-term follow-up study of ZOSTER-049 (follow-up of ZOSTER-006/022 studies) to assess the prophylactic efficacy, safety and persistence of imm...
    Medical condition: Vaccination against HZ and its related complications in adults older than 50 years (at the time of primary vaccination).
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019974 Herpes zoster PT
    21.1 10029205 - Nervous system disorders 10036376 Post herpetic neuralgia PT
    20.1 10021881 - Infections and infestations 10030865 Ophthalmic herpes zoster PT
    20.0 10021881 - Infections and infestations 10063491 Herpes zoster oticus PT
    21.1 10021881 - Infections and infestations 10075611 Varicella zoster virus infection PT
    20.0 10021881 - Infections and infestations 10074297 Herpes zoster cutaneous disseminated PT
    23.1 10021881 - Infections and infestations 10080516 Herpes zoster reactivation PT
    23.1 10021881 - Infections and infestations 10084396 Disseminated varicella zoster virus infection PT
    20.0 10021881 - Infections and infestations 10072210 Genital herpes zoster PT
    20.1 10021881 - Infections and infestations 10061208 Herpes zoster infection neurological PT
    20.0 10021881 - Infections and infestations 10074259 Herpes zoster meningitis PT
    20.0 10021881 - Infections and infestations 10074248 Herpes zoster meningoencephalitis PT
    20.0 10021881 - Infections and infestations 10074243 Varicella zoster oesophagitis PT
    21.1 10021881 - Infections and infestations 10074254 Varicella zoster pneumonia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) SE (Trial now transitioned) FR (Trial now transitioned) FI (Trial now transitioned) EE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 23:03:49 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA